MyFinsight
Home
Blog
About
Contact
pmcb: the income statement
Download
Download image
Net income (loss)
attributable to common...
-$8,416,610
(-184.45%↓ Y/Y)
Preferred stock accretion
$901,996
(-13.71%↓ Y/Y)
Preferred stock dividends
$96,639
(-78.23%↓ Y/Y)
Net income (loss)
-$7,417,975
(-404.78%↓ Y/Y)
Total other income and
(expense), net
-$6,041,924
(-1562.15%↓ Y/Y)
Loss from operations
-$1,376,051
(-24.41%↓ Y/Y)
Gain on related party
investment - qcls
$2,089,000
Change in fair value of
warrants - qcls
$6,050,000
Change in fair value of
convertible note receivable...
$392,000
(-9.89%↓ Y/Y)
Change in fair value of
derivative liability
$302,000
(-69.18%↓ Y/Y)
Interest income
$206,387
(-46.05%↓ Y/Y)
Other expense
-$95
(91.05%↑ Y/Y)
Unrealized loss on
marketable securities
-$60,663
Loss on issuance of
series c convertible...
-$215,000
Issuance costs series c
convertible preferred stock...
-$1,234,553
Change in fair value of
investment - qcls
-$2,371,000
Change in fair value of
warrant asset - femasys
-$726,000
(-363.04%↓ Y/Y)
Change in fair value of
warrant liability
-$10,474,000
(-672.66%↓ Y/Y)
Total operating
expenses
$1,376,051
(24.41%↑ Y/Y)
General and
administrative
$1,234,966
(950.39%↑ Y/Y)
Research and development
costs
$141,085
(44.75%↑ Y/Y)
Back
Back
Income Statement
source: myfinsight.com
PharmaCyte Biotech, Inc. (PMCB)
PharmaCyte Biotech, Inc. (PMCB)